Northern Trust Corp boosted its position in Cara Therapeutics, Inc. (NASDAQ:CARA) by 33.5% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 329,070 shares of the biopharmaceutical company’s stock after purchasing an additional 82,553 shares during the quarter. Northern Trust Corp owned about 1.01% of Cara Therapeutics worth $5,064,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of CARA. Morgan Stanley lifted its position in Cara Therapeutics by 360.3% in the 1st quarter. Morgan Stanley now owns 332,606 shares of the biopharmaceutical company’s stock valued at $6,117,000 after purchasing an additional 260,344 shares during the last quarter. Vanguard Group Inc. lifted its position in Cara Therapeutics by 20.0% in the 1st quarter. Vanguard Group Inc. now owns 943,627 shares of the biopharmaceutical company’s stock valued at $17,353,000 after purchasing an additional 156,958 shares during the last quarter. Quantitative Investment Management LLC bought a new stake in Cara Therapeutics in the 2nd quarter valued at about $2,186,000. Swiss National Bank bought a new stake in Cara Therapeutics in the 2nd quarter valued at about $651,000. Finally, Bank of New York Mellon Corp lifted its position in Cara Therapeutics by 26.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 177,766 shares of the biopharmaceutical company’s stock valued at $2,735,000 after purchasing an additional 36,769 shares during the last quarter. Hedge funds and other institutional investors own 61.03% of the company’s stock.

Cara Therapeutics, Inc. (CARA) opened at $12.18 on Friday. Cara Therapeutics, Inc. has a 52 week low of $8.61 and a 52 week high of $28.50.

Cara Therapeutics (NASDAQ:CARA) last announced its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.03). During the same period in the prior year, the business earned ($0.42) EPS. analysts forecast that Cara Therapeutics, Inc. will post -1.84 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Northern Trust Corp Purchases 82,553 Shares of Cara Therapeutics, Inc. (CARA)” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.watchlistnews.com/northern-trust-corp-purchases-82553-shares-of-cara-therapeutics-inc-cara/1711151.html.

In other news, CEO Derek T. Chalmers sold 16,000 shares of Cara Therapeutics stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $12.66, for a total value of $202,560.00. Following the transaction, the chief executive officer now owns 1,066,292 shares of the company’s stock, valued at approximately $13,499,256.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 7.70% of the company’s stock.

Several analysts recently weighed in on CARA shares. Zacks Investment Research upgraded shares of Cara Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a research report on Wednesday, August 30th. Scotiabank lifted their price objective on shares of Cara Therapeutics from $31.00 to $31.50 and gave the company an “outperform” rating in a research report on Tuesday, October 17th. BidaskClub downgraded shares of Cara Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Cara Therapeutics in a research report on Friday, August 4th. Finally, BMO Capital Markets reiterated a “market perform” rating and issued a $25.00 price objective on shares of Cara Therapeutics in a research report on Tuesday, November 7th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $25.17.

Cara Therapeutics Profile

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.

Institutional Ownership by Quarter for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.